Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

Keywords

• Temsirolimus
• Chromophobe renal cell cancer
• Liver metastases
• Sunitinib
• Sorafenib